We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
TODAY'S HIGH
3022.35
TODAY'S LOW
2862
52 WEEK HIGH
4350
52 WEEK LOW
2801
% of Shares Held by
All Insider
67.76%
% of Shares Held by
Institutions
20.56%
% of Float Held by
Institutions
63.79%
Number of Institutions
Holding Shares
82
MARKET CAP
47831.59 Cr.
ETERPRISE VALUE
47129.40 Cr.
NO. OF SHARES
16.45 Cr.
BOOK VALUE
435.613
DIV. YIELD
None%
DEBT
4.74 Cr.
GROSS PROFIT
0
CASH
3248.31 Cr.
REVENUE
''
REVENUE/SHARE
None
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | -1357.59 Cr. | -638.74 Cr. | -218.74 Cr. |
| Change To Liabilities | 0 | 142.81 Cr. | -214.67 Cr. | 113.01 Cr. |
| Total cashflows from Investing Activities | 0 | -1524 Cr. | -766.07 Cr. | -314.13 Cr. |
| Net Borrowings | 0 | -1.01 Cr. | -62 Lakhs | -50.70 Lakhs |
| Total Cash from Financing Activities | 0 | 1238.46 Cr. | -6.87 Cr. | -3.12 Cr. |
| Other Liabilities | 0 | 51.40 Lakhs | 59.65 Cr. | -22.01 Cr. |
| Total Assets | 0 | 1241.80 Cr. | 1241.80 Cr. | 1241.80 Cr. |
| Net Income | 0 | 996.96 Cr. | 772.85 Cr. | 451.85 Cr. |
| Change in Cash | 0 | 322.96 Cr. | -66.90 Cr. | -136.43 Cr. |
| Effect of Exchange Rate | 0 | 3.57 Cr. | 5.10 Cr. | -4.43 Cr. |
| Total Cash from Operating Activities | 0 | 604.92 Cr. | 700.93 Cr. | 185.25 Cr. |
| Depreciation | 0 | 98.78 Cr. | 94.58 Cr. | 82.12 Cr. |
| Other Cashflows from Investing Activities | 0 | 61.93 Cr. | 43.44 Cr. | 39.80 Cr. |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Change to Inventory | 0 | -518.88 Cr. | 155.59 Cr. | -399.04 Cr. |
| Change to Account Receivables | 0 | -60.20 Cr. | -80.51 Cr. | -45.89 Cr. |
| Other Cashflows from Financing Activities | 0 | -2.33 Cr. | -6.25 Cr. | -2.61 Cr. |
| Change to Net Income | 0 | -55.05 Cr. | -86.56 Cr. | 5.22 Cr. |
| Capital Expenditures | 0 | -228.77 Cr. | -194.66 Cr. | -135.74 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 0 | 1334.81 Cr. | 992.86 Cr. | 686.27 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 0 | 1203.44 Cr. | 860.88 Cr. | 624.38 Cr. |
| Selling General Administrative | 0 | 312.18 Cr. | 278.42 Cr. | 223.75 Cr. |
| Gross Profit | 0 | 1853.21 Cr. | 1417.76 Cr. | 1080.17 Cr. |
| Ebit | 0 | 1203.44 Cr. | 860.88 Cr. | 624.38 Cr. |
| Operating Income | 0 | 1203.44 Cr. | 860.88 Cr. | 624.38 Cr. |
| Other Operating Expenses | 0 | 238.52 Cr. | 182.25 Cr. | 140.44 Cr. |
| Interest Expense | 0 | -2.91 Cr. | -6.25 Cr. | -2.61 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 0 | 337.84 Cr. | 220 Cr. | 234.42 Cr. |
| Total Revenue | 0 | 3462.87 Cr. | 2633.24 Cr. | 2044.20 Cr. |
| Total Operating Expenses | 0 | 2259.43 Cr. | 1772.36 Cr. | 1419.82 Cr. |
| Cost of Revenue | 0 | 1609.66 Cr. | 1215.47 Cr. | 964.02 Cr. |
| Total Other Income Expense Net | 0 | 131.36 Cr. | 131.98 Cr. | 61.89 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 0 | 996.96 Cr. | 772.85 Cr. | 451.85 Cr. |
| Net Income Applicable to Common Shares | 0 | 996.96 Cr. | 772.85 Cr. | 451.85 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 0 | 0 | 0 | 0 |
| Capital Surplus | 0 | 1840.10 Cr. | 588.99 Cr. | 588.99 Cr. |
| Total Liabilities | 0 | 592.84 Cr. | 439.80 Cr. | 661.55 Cr. |
| Stock Holder Equity | 0 | 5903.24 Cr. | 3646.23 Cr. | 2861.99 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 80.04 Cr. | 64.31 Cr. | 61.28 Cr. |
| Total Assets | 0 | 6496.08 Cr. | 4086.03 Cr. | 3523.54 Cr. |
| Common Stock | 0 | 16.35 Cr. | 15.49 Cr. | 15.49 Cr. |
| Retained Earnings | 0 | 4025.80 Cr. | 3028.84 Cr. | 2255.86 Cr. |
| Other Liabilities | 0 | 75.61 Cr. | 75.78 Cr. | 122.77 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | 0 | 20.97 Cr. | 12.90 Cr. | 1.64 Cr. |
| Other Assets | 0 | 80.40 Cr. | 83.18 Cr. | 113.22 Cr. |
| Cash | 0 | 492.46 Cr. | 169.49 Cr. | 236.40 Cr. |
| Current Liabilities | 0 | 512.52 Cr. | 359.02 Cr. | 532.76 Cr. |
| Long Term Asset Charges | 0 | 0 | 0 | 0 |
| Short Long Term Debt | 0 | 13.50 Lakhs | 89.10 Lakhs | 53 Lakhs |
| Other Stockholder Equity | 0 | 20.97 Cr. | 12.90 Cr. | 1.64 Cr. |
| Property Plant Equipment | 0 | 1292.03 Cr. | 1156.56 Cr. | 1052.87 Cr. |
| Total Cur. Assets | 0 | 5123.64 Cr. | 2846.29 Cr. | 2357.45 Cr. |
| Long Term Investments | 0 | 0 | 0 | 0 |
| Net Tangible Assets | 0 | 5903.24 Cr. | 3646.23 Cr. | 2861.99 Cr. |
| Short Term Investments | 0 | 2510.68 Cr. | 1142.72 Cr. | 484.34 Cr. |
| Net Receivables | 0 | 744.46 Cr. | 664.39 Cr. | 552.04 Cr. |
| Long Term Debt | 0 | 3.93 Cr. | 4.06 Cr. | 4.96 Cr. |
| Inventory | 0 | 1288.16 Cr. | 771.35 Cr. | 922.71 Cr. |
| Accounts Payable | 0 | 400.72 Cr. | 249.09 Cr. | 446.19 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account